Compare Stocks → The #1 Crypto for AI (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALDXNASDAQ:CNCENASDAQ:IMVNASDAQ:SAVANASDAQ:UROV Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$4.16-1.2%$3.70$1.42▼$11.97$247.15M1.45568,144 shs319,594 shsCNCEConcert Pharmaceuticals$8.37$8.37$2.66▼$8.55$401.26M0.522.97 million shsN/AIMVIMV$0.66$0.48▼$12.70$9.63M0.95233,607 shs44,800 shsSAVACassava Sciences$22.050.0%$21.37$12.32▼$32.10$953.66M-0.38781,318 shs1.14 million shsUROVUrovant Sciences$16.24$16.23$7.15▼$16.26$531.75M2.36114,469 shsN/A12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics-1.19%+5.85%+0.24%+30.82%-59.14%CNCEConcert Pharmaceuticals0.00%0.00%0.00%0.00%0.00%IMVIMV0.00%0.00%0.00%0.00%0.00%SAVACassava Sciences-0.05%-1.30%+7.14%-7.31%+38.37%UROVUrovant Sciences0.00%0.00%0.00%0.00%0.00%Automatic Income (from home) (Ad)For over 22 years, Wall Street elites have kept this little-known "income hack" from everyday investors… 6 simple clicks have set up HUGE payouts for "in-the-know" investors… Delivering them passive income 365 days a year. Just click here now to watch my presentation for free.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALDXAldeyra Therapeutics1.7896 of 5 stars3.52.00.00.02.22.50.0CNCEConcert PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AIMVIMVN/AN/AN/AN/AN/AN/AN/AN/ASAVACassava Sciences3.2256 of 5 stars3.50.00.04.72.30.00.6UROVUrovant SciencesN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALDXAldeyra Therapeutics3.00Buy$9.33124.36% UpsideCNCEConcert PharmaceuticalsN/AN/AN/AN/AIMVIMVN/AN/AN/AN/ASAVACassava Sciences3.00Buy$124.00462.36% UpsideUROVUrovant SciencesN/AN/AN/AN/ACurrent Analyst RatingsLatest CNCE, UROV, SAVA, IMV, and ALDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/3/2024ALDXAldeyra TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$10.004/2/2024ALDXAldeyra TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.003/5/2024SAVACassava SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$124.00(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALDXAldeyra TherapeuticsN/AN/AN/AN/A$2.04 per shareN/ACNCEConcert Pharmaceuticals$32.58M12.32N/AN/A$3.24 per share2.58IMVIMV$330K0.00N/AN/A($0.69) per share0.00SAVACassava SciencesN/AN/AN/AN/A$3.26 per shareN/AUROVUrovant SciencesN/AN/AN/AN/A($1.90) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALDXAldeyra Therapeutics-$37.54M-$0.64N/AN/AN/AN/A-29.45%-24.24%8/1/2024 (Estimated)CNCEConcert Pharmaceuticals-$80.05M-$3.21N/AN/AN/AN/A-109.43%-76.65%N/AIMVIMV-$37.99M-$4.59N/AN/AN/A-11,547.42%-12,695.41%-104.84%N/ASAVACassava Sciences-$97.22M-$2.32N/A13.20N/AN/A-57.53%-52.58%5/6/2024 (Estimated)UROVUrovant Sciences-$146.74M-$4.71N/AN/AN/AN/AN/A-162.90%N/ALatest CNCE, UROV, SAVA, IMV, and ALDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/7/2024Q4 2023ALDXAldeyra Therapeutics-$0.21-$0.08+$0.13-$0.08N/AN/A2/28/2024Q4 2023SAVACassava Sciences-$0.40-$0.50-$0.10-$0.50N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALDXAldeyra TherapeuticsN/AN/AN/AN/AN/ACNCEConcert PharmaceuticalsN/AN/AN/AN/AN/AIMVIMVN/AN/AN/AN/AN/ASAVACassava SciencesN/AN/AN/AN/AN/AUROVUrovant SciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALDXAldeyra TherapeuticsN/A6.646.64CNCEConcert PharmaceuticalsN/A9.039.03IMVIMVN/A2.932.93SAVACassava SciencesN/A9.139.13UROVUrovant SciencesN/A2.912.91OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALDXAldeyra Therapeutics59.71%CNCEConcert Pharmaceuticals70.63%IMVIMV15.37%SAVACassava Sciences38.05%UROVUrovant Sciences18.44%Insider OwnershipCompanyInsider OwnershipALDXAldeyra Therapeutics7.30%CNCEConcert Pharmaceuticals11.33%IMVIMV0.33%SAVACassava Sciences9.00%UROVUrovant Sciences2.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALDXAldeyra Therapeutics1559.41 million55.08 millionOptionableCNCEConcert Pharmaceuticals6447.94 million42.51 millionOptionableIMVIMV9711.71 million11.67 millionOptionableSAVACassava Sciences2943.25 million39.35 millionOptionableUROVUrovant Sciences7032.74 millionN/ANot OptionableCNCE, UROV, SAVA, IMV, and ALDX HeadlinesSourceHeadlinePierre Fabre Laboratories receive positive CHMP opinion for OBGEMSA(vibegron) in overactive bladder syndromefinanznachrichten.de - April 26 at 1:33 PMPierre Fabre Laboratories receive positive CHMP opinion for OBGEMSA™(vibegron) in overactive bladder syndromefinance.yahoo.com - April 26 at 1:33 PMOC Drugmakers Cut Headcounts, Close Officesocbj.com - April 22 at 7:23 PMA2 Bio’s new CEO aims to grow platformpacbiztimes.com - April 8 at 6:15 AMC-Suite Shuffle: A2 Bio, Bayer, BioNTech and Morebiospace.com - March 27 at 2:46 AMA2 Bio Appoints James Robinson as New Chief Executive Officer and Member of the Board of Directorsfinance.yahoo.com - March 26 at 3:06 AMHEALTH BEHAVIOR AND NUTRITION SCIENCESudel.edu - February 17 at 2:30 PMBulletin Science and Security Boardthebulletin.org - February 15 at 3:32 PMSecretary-General’s Guidance Note on Behavioural Scienceun.org - February 5 at 9:35 AMMarine Sciences & Technologyuml.edu - January 7 at 12:52 PMThe 7 Best Science Kits for Kids and Teenspopularmechanics.com - December 22 at 12:32 AMCareers in Computer Sciencemccormick.northwestern.edu - December 11 at 10:18 AMPhD in Information Sciencedrexel.edu - December 8 at 10:01 AMPetauri™ Elects William Fleming and James Robinson to Its Board of Directorsfinance.yahoo.com - December 6 at 10:09 AMCore Requirements & Coursesbc.edu - December 1 at 1:25 PMInspiring Women in Sciencenature.com - November 28 at 10:11 AMDevelop your own cognitive toolkit.miamioh.edu - November 17 at 9:55 AMBenign Prostatic Hyperplasia Market Size in 7MM is expected to witness a major change in the study period 2019–2032, estimates DelveInsightmedgadget.com - November 16 at 8:17 AMPM360 Announces 2023 Trailblazer Award Winnersfinance.yahoo.com - October 4 at 8:59 AMHeavy Drinking Not Tied to Lower Response to DAAs for Hepatitis Cmedpagetoday.com - September 26 at 3:23 PMEledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directorsfinance.yahoo.com - September 11 at 8:30 AMClinical and Translational Science Institutebuffalo.edu - September 8 at 9:36 PMMDxHealth CEO Bullish After Q2 Revenue Boostocbj.com - September 5 at 8:49 PMWindmill Model Science Projecteducation.com - August 15 at 1:51 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAldeyra TherapeuticsNASDAQ:ALDXAldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.Concert PharmaceuticalsNASDAQ:CNCEConcert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.IMVNASDAQ:IMVIMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. Its immune-educating technology includes DPX which is designed to inform a specific, coordinated, and persistent anti-tumor immune response. The company was founded on May 18, 2007 and is headquartered in Dartmouth, Canada.Cassava SciencesNASDAQ:SAVACassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.Urovant SciencesNASDAQ:UROVUrovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.